Non-vitamin K antagonist oral anticoagulants (NOACs) and valvular heart disease with AF

Non-vitamin K antagonist oral anticoagulants (NOACs) and valvular heart disease with AF Subgroup analysis of certain clinical trials support the use of rivaroxaban, apixaban, dabigatran and edoxaban in patients with aortic stenosis, aortic regurgitation or mitral regurgitation having atrial fibrillation. NOACs can also be used in aortic bioprosthesis with atrial fibrillation if the valve has been implanted more than 3 months back. NOACs are better avoided in those with moderate or severe mitral stenosis and atrial fibrillation in view of high thromboembolic risk. NOACs should not be used in those with mechanical prosthetic valve with or without atrial fibrillation. Those patients still require vitamin K antagonists like warfarin for anticoagulation, of course with regular monitoring of prothrombin time international normalized ratio. Reference Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017 Sep 21;38(36):2739-2791.
Source: Cardiophile MD - Category: Cardiology Authors: Tags: General Cardiology Source Type: blogs